Market Place
Sourcing Support
Menarini Group & Medsir Present Ph 3 ADELA Study for Breast Cancer
11 Dec 2024 //
BUSINESSWIRE
Insilico nabs $500M+ biobucks deal for preclinical cancer asset
04 Jan 2024 //
FIERCE BIOTECH
Stemline Therapeutics` Orserdu (elacestrant) Receives Approval in Europe
09 Oct 2023 //
EMA
Menarini`s Orserdu granted EU nod for advanced breast cancer
21 Sep 2023 //
BUSINESSWIRE
The Menarini Group Announces ELZONRIS Designated as an Orphan Drug for BPDCN
30 Aug 2023 //
BUSINESSWIRE
Stemline`s Biologic Elzonris (Tagraxofusp) Receives Approval in the U.S.
03 Nov 2022 //
FDA
Stemline`s Biologic Elzonris (Tagraxofusp) Receives Approval in the U.S.
27 Oct 2022 //
FDA
Menarini`s Elacestrant MAA Accepted for Review by EMA
19 Aug 2022 //
BUSINESSWIRE
Menarini`s filing for oral SERD elacestrant gets FDA priority review
12 Aug 2022 //
BUSINESSWIRE
Menarini Group Completes Acquisition of Stemline Therapeutics
10 Jun 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.